10 results
6-K
EX-99.1
TAK
Takeda Pharmaceutical Co
29 May 24
Current report (foreign)
6:29am
a decade of intense pricing pressure that directly compromised the industry’s capacity to innovate. There are still harsh price reductions being implemented … to succeed in this future. We are encouraging our people to adopt a digital-first mindset and innovate with technology in every aspect of our work, because we
6-K
EX-99.1
TAK
Takeda Pharmaceutical Co
30 May 23
Current report (foreign)
6:19am
to sales, profit and margin growth in the near-term. We will continue to invest in R&D and data and technology to innovate and secure long- term
6-K
EX-99.1
TAK
Takeda Pharmaceutical Co
30 Nov 22
Current report (foreign)
6:28am
continues to innovate and deliver for patients with life-threatening conditions. Oncology, with 225.3 billion yen in reported revenue, declined -12
6-K
EX-99.1
si0 1gwou6wn728n
30 Nov 21
Current report (foreign)
6:04am
6-K
EX-99.1
vwrsv14 avbd8qn
29 Jun 21
Current report (foreign)
7:38am
6-K
EX-99.1
q6wa3xg2i8 o7tao
17 Dec 20
Current report (foreign)
6:01am
6-K
EX-99.1
vqjiio32zniv8
10 Jan 20
Better Health, Brighter Future 2019 SUSTAINABLE VALUE REPORT Takeda Pharmaceutical Company Limited
6:36am
- Prev
- 1
- Next